European Drug Report 2026: Trends and Developments: source data

This data bundle contains all of the source data tables for the European Drug Report 2026: Trends and Developments. These data tables are used to generate the data visualisations and other tables in the report. Links to the source data tables  to create data visualisations for specific sections can also be found at the bottom of each page, as well as, in most cases, beneath each graphic.

Notes:

• Note that the data set presented on this page is only a small subset of the data collected through our partner organisations. For more data and statistics, as well as for detailed methodological notes, caveats, please consult the Statistical Bulletin 2026, launched alongside this report.
• Unless otherwise stated, all data sets are fully compatible with the Creative Commons Attribution 4.0 International (CC BY 4.0) licence. This means you are free to re-use our data and statistic in your work and research, provided you acknowledge us as the source.
• All files are in CSV (comma separated values) format which may be open by most spreadsheet or statistical software.

Methodological notes

Prevalence of drug use data

• Prevalence data presented here are based on general population surveys submitted to the EUDA by Reitox national focal points. For the latest data and detailed methodological information please see the Statistical Bulletin 2026: Prevalence of drug use.
• Graphics showing the most recent country-level data are based on studies carried out between 2015 and 2024.
• ‘Amphetamines’ covers both amphetamine and methamphetamine. Prevalence data presented here are based on general population surveys submitted to the EUDA by national focal points.
• Cannabis prevalence estimates for the general population: age ranges are 18-64 and 18-34 for Germany, Greece, France, Italy and Hungary; 16-64 and 16-34 for Denmark, Estonia, Sweden and Norway; 18-65 and 18-34 for Malta.
• Cocaine prevalence estimates: age ranges are 18-64 and 18-34 for Germany, Greece, France, Italy and Hungary; 16-64 and 16-34 for Denmark, Estonia and Norway; 18-65 and 18-34 for Malta; 17-34 for Sweden.
• Amphetamines prevalence estimates for the general population: age ranges are 18-64 and 18-34 for Germany, Greece, France, Italy and Hungary; 16-64 and 16-34 for Denmark, Estonia and Norway; 18-34 for Malta; 17-34 for Sweden.
• MDAM / 'ecstasy' prevalence estimates for the general population: age ranges are 18-64 and 18-34 for Germany, Greece, France, Italy and Hungary; 16-64 and 16-34 for Denmark, Estonia and Norway; 18-65 and 18-34 for Malta; 17-34 for Sweden.

Treatment demand data

•  Apart from the trends, data are for all treatment entrants with the substance as the primary drug – 2024 or the most recent year available.
• Trends in first-time entrants are based on 26 countries. Only countries with data for at least 6 of the 7 years are included in the trends analysis. Missing values are interpolated from adjacent years. Because of disruptions to services due to COVID-19, data for 2020, 2021 and 2022 should be interpreted with caution. Missing data were imputed with values from the previous year for Spain and France (2024) and Germany (2019). In Germany, trends are affected by the near disappearance of referrals from the criminal justice system following legislation change in February 2024. 
• Routes of administration, heroin: ‘Other routes’ include eating/drinking, sniffing and unspecified main routes of administration. Trends are based on the 19 EU Member States providing data over the period; only those with data for at least 9 of the 11 years are included. Missing values are interpolated from adjacent years. Because of disruptions to services due to COVID-19, data for 2020, 2021 and 2022 should be interpreted with caution.

Supply and markets data

• Indexed trends presented reflect relative changes in drug seizures over a 10-year period but give no indication of the actual amounts.
• MDMA tablets were converted to mass-equivalents by assuming a mass of 0.25 grams MDMA per tablet.
• EU+2 refers to EU Member States, Norway and Türkiye.
• Price and potency: mean national values – minimum, maximum and interquartile range. Countries vary by indicator.

Wastewater data

• Mean daily amounts of target are given in milligrams per 1 000 population. In most cities, sampling was carried out over a week between March and May 2025.
• Taking into account statistical errors, values that differ by less than 10% from the previous value are considered stable in tables showing changes between 2024 and 2025.
• Source: Sewage Analysis Core Group Europe (SCORE)
• For the complete data set and analysis, see Wastewater analysis and drugs – a European multi-city study.

Euro-DEN Plus data

• For year-on-year changes data, values that differ by less than 10% from the previous value are considered stable. Only centres reporting at least 20 presentations for each year are represented.
• In Bratislava, Bucharest, Gdansk and Riga, there were 10 or fewer cocaine-related presentations in 2024, limiting comparability between years. For the latest data and detailed methodological information please see: Euro-DEN data explorer.

Drug-checking data

• Trans-European Drug Information network (TEDI). Data from 11 European drug checking services in 7 EU Member States, 2024 and 2025.

Drug-induced deaths data

• Proportion of deaths with opioids mentioned: data from special mortality registers. Countries with at least 70 cases reported are included. Countries are sorted in descending order by the proportion of cases involving heroin. In some countries, the details on the exact opioids involved are missing. 
• Trends data: comparable data for Germany are not available before 2021. For trend visualisation, earlier years were populated using the first available data point. However, according to the national definition used at the time, drug-induced deaths in Germany increased up to 2020. Data are not available for some countries for 2023 or 2024. In those cases, the most recent available data were used in place of the missing values (2022 for Belgium, Ireland, Greece; 2023 for Spain, France, Poland, Portugal).

Harm reduction data

• Needle and syringe distribution and opioid agonist treatment coverage in relation to WHO 2025 targets: the coverage is based on the latest national estimates of injecting drug use and high-risk opioid use matched by harm reduction activity data (within a maximum of 2 years). The estimate of coverage of opioid agonist treatment for Belgium is derived from a subnational study conducted in 2019.
• Take-home naloxone: Data are for EU Member States, Norway and Türkiye in 2024. In Greece in 2023, a law was issued for take-home naloxone; in 2025, a ministerial decree was issued allowing the implementation of the programme.